Lisata Therapeutics Inc (LSTA)

[whirlybird]

There will be huge amounts of cash down the road
From NBS Investor Presentation Mar 2014

COMMERCIAL MANUFACTURING CONTRACT FOR PCT
Est. Peak Annual Sales
2,500 to 5,000 Units $38M to $75M / Yr.
10,000 to 25,000 Units $80M to $200M / Yr.
25,000 to 50,000 Units. $125 to $250M / Yr

Conservatively when Baxter commercializes the PCT CD34-Positive Cells for AMI following completion of the RESERVE study this year, at least 50,000 units will be sold in treating AMI. At that time enough cash could come into NBS coffers to equal the current capitalization. The COGS would then compel Baxter to make a tender offer.